Table 3.
Therapy of 124 TNBC patients assessed for BRCA1/2 mutations.
| Type of therapy | Patients tested for BRCA mutations | p value (BRCA-positive vs BRCA-negative) | |||
|---|---|---|---|---|---|
| BRCA noncarriers | Rate (%) | BRCA carriers | Rate (%) | ||
| Number of patients | 94 | 100 | 30 | 100 | |
|
| |||||
| Surgery | |||||
| Yes | 90 | 96 | 29 | 97 | 0.7004 |
| No | 4 | 4 | 1 | 3 | |
|
| |||||
| Type of surgery | |||||
| Mastectomy | 60/90 | 66.5 | 17/29 | 58.5 | 0.2438 |
| Breast-conserving surgery | 30/90 | 33.5 | 12/29 | 41.5 | |
|
| |||||
| Radiotherapy | |||||
| Yes | 55 | 58.5 | 17 | 56.5 | 0.7751 |
| No | 39 | 41.5 | 13 | 43.5 | |
|
| |||||
| Radiotherapy | |||||
| After mastectomy | 27/55 | 49 | 5/17 | 29.5 | 0.0044 |
| After breast-conserving surgery | 28/55 | 51 | 12/17 | 70.5 | |
|
| |||||
| Neoadjuvant chemotherapy | |||||
| Yes | 20 | 21.5 | 4 | 13.5 | 0.0940 |
| No | 74 | 78.5 | 26 | 86.5 | |
|
| |||||
| Regimens in neoadjuvant chemotherapy | |||||
| AT⟶CMF | 5/20 | 25 | 1/4 | 25 | <0.0001 |
| Anthracycline + taxane | 9/20 | 45 | 2/4 | 50 | |
| Anthracycline | 5/20 | 5 | 1/4 | 25 | |
| Others | 1/20 | 25 | 0 | 0 | |
|
| |||||
| Adjuvant chemotherapy | |||||
| Yes | 64 | 68 | 23 | 76.5 | 0.1541 |
| No | 30 | 32 | 7 | 23.5 | |
|
| |||||
| Regimens in adjuvant chemotherapy | |||||
| Anthracycline (AC) | 41/64 | 64 | 12/23 | 52 | 0.0574 |
| FEC/FAC | 11/64 | 17.5 | 4/23 | 17.5 | |
| Anthracycline + taxane | 8/64 | 12.5 | 5/23 | 21.5 | |
| CMF | 2/64 | 3 | 0 | 0 | |
| Taxane | 2/64 | 3 | 2/23 | 9 | |